Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 2
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a peri…
Recurrent GliomaRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
National Cancer Institute (NCI)NCT05859334
Phase 1
A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has c…
Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern UniversityNCT06410248
Phase 1
A Phase I, Dose-Escalation Trial of Anti-GARP Chimeric Antigen Receptor-T Cell Therapy in Patients With Recurrent High-Grade Glioma Treated at a Single Medical Center
This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell t…
Recurrent Malignant GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 Glioma+3 more
Ohio State University Comprehensive Cancer CenterNCT06964737
Phase 3
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with n…
Low Grade AstrocytomaLow Grade GliomaMetastatic Low Grade Astrocytoma+3 more
National Cancer Institute (NCI)NCT04166409